Advertisement

Topics

Aadi Bioscience, Inc. Company Profile

03:52 EDT 19th June 2019 | BioPortfolio

Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE and the albumin-based technology platform. Aadi’s lead product nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009) is an mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation, mTOR target suppression and improved efficacy over other mTOR inhibitors in preclinical models. mTOR as a therapeutic target is well recognized in oncology, however Aadi aims to develop the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing. Aadi’s ongoing and planned clinical trials include Oncology (first-line treatment of advanced colorectal cancer with respect to PTEN status, pediatric tumors, advanced sarcoma, newly diagnosed and recurrent glioblastoma, advanced neuroendocrine tumors), Cardiovascular indications (pulmonary arterial hypertension), CNS indications (surgically refractory epilepsy) and Mitochondrial disease (Leigh Syndrome).


News Articles [376 Associated News Articles listed on BioPortfolio]

FDA Grants Breakthrough Therapy Designation for Aadi Bioscience’s Tarzifyx in PEComa Indication

PACIFIC PALISADES, Calif.–(BUSINESS WIRE)–Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced t...

Aadi Bioscience Receives Breakthrough Therapy Designation for TARZIFYX™ (ABI-009) in PEComa Indication

Lead Registration study in Advanced Malignant PEComa completes enrollment and company is On-Track for 2019 NDA Filing Aadi to present at Biotech Showcase Conference (held...

Aytu BioScience, Inc.: Aytu BioScience Appoints Steven Boyd to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant m...

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

Aytu BioScience, Inc.: Aytu BioScience Reports 291% Revenue Growth in Q3 FY19

Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel pr...

Aytu BioScience, Inc.: Aytu BioScience to Present at 11th Annual LD Micro Main Event Investor Conference on December 5, 2018

ENGLEWOOD, CO / ACCESSWIRE / November 27, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significan...

Aytu BioScience, Inc.: Aytu BioScience to Report Fiscal Third Quarter 2019 Results and Business Update

Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / ACCESSWIRE / May 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focu...

Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH(TM) Technology

Lexaria Bioscience Corp. (CSE:LXX,OCTQX:LXRP) a wholly owned subsidiary of Lexaria Bioscience Corp. has entered into a definitive agreement with Altria Group Inc. (NYSE: MO) to fund the research �...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Idkit hp one [exalenz bioscience ltd.]

Package Insert IDkit:Hp™ for the Exalenz BreathID® System BREATH TEST FOR DETECTION of H. pylori

Natesto [aytu bioscience, inc.]

These highlights do not include all the information needed to use NATESTO safely and effectively. See full prescribing information for NATESTO.Natesto (testosterone) nasal gel CIII Initial U.S. Approv...

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

AADI Glaucoma Shunt - a Quality Control Study

To prospectively investigate the effect and safety of implantation of the AADI glaucoma tube in eyes with medically intractable glaucoma in the period 2019 to 2020, at the Department of Op...

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Trial of HPV Vaccine in Healthy Adult and Adolescent Female

This is a randomized, double-blind, active-controlled, phaseI/II clinical trial to enroll 200 healthy female including 80 healthy adult aged 19 to 26 years and 120 adolescents aged 9 to 13...

The Pregnancy & Early Life Study

The gut is home to a diverse and dynamic microbial community, termed the microbiota. The microbiota is essential for health and wellbeing and is involved in acquisition of nutrients and en...

Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

This pilot study will try to minimize the pain during exposure to a new red light source (RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without compromising it...

Companies [318 Associated Companies listed on BioPortfolio]

Aadi Bioscience, Inc.

Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE and the albumin-based technology platform. Aadi’s lead product nab-sirolimus...

AADi, LLC

The Idaho Bioscience Association

The Idaho Bioscience Association is a non-profit organization that brings together corporate, academic and political leaders to educate the public and to promote bioscience activities in the state. B...

Sprint Bioscience

Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry. The company has the goal to develop drug candidates for the global pharmaceutical market within the...

Bioscience Bridge, LLC

Bioscience Bridge, LLC is a global technology transfer agency. We accelerate the connections of university-based bioscience research with commercial development opportunities. We are unique because we...

More Information about "Aadi Bioscience, Inc." on BioPortfolio

We have published hundreds of Aadi Bioscience, Inc. news stories on BioPortfolio along with dozens of Aadi Bioscience, Inc. Clinical Trials and PubMed Articles about Aadi Bioscience, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aadi Bioscience, Inc. Companies in our database. You can also find out about relevant Aadi Bioscience, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record